M
Mark I. James
Researcher at Leicester Royal Infirmary
Publications - 5
Citations - 425
Mark I. James is an academic researcher from Leicester Royal Infirmary. The author has contributed to research in topics: Colorectal cancer & Cancer. The author has an hindex of 4, co-authored 4 publications receiving 312 citations. Previous affiliations of Mark I. James include University of Leicester.
Papers
More filters
Journal ArticleDOI
Cancer chemoprevention: Evidence of a nonlinear dose response for the protective effects of resveratrol in humans and mice
Hong Cai,Edwina N. Scott,Abeer O. Kholghi,Catherine Andreadi,Alessandro Rufini,Ankur Karmokar,Robert G. Britton,Emma Horner-Glister,Peter Greaves,Dhafer Jawad,Mark I. James,Lynne M. Howells,Ted J. Ognibene,Michael A. Malfatti,Christopher E. Goldring,Neil R. Kitteringham,Joanne Walsh,Maria Viskaduraki,Kevin West,Andrew S. Miller,David Hemingway,William P. Steward,Andreas J. Gescher,Karen Brown +23 more
TL;DR: It is shown that a low rather than a high dose of resveratrol prevents tumor growth in mice and alters metabolic pathways in human tissues and suggests that it's time for a revision in development strategies for preventative dietary agents.
Journal ArticleDOI
Curcumin inhibits cancer stem cell phenotypes in ex vivo models of colorectal liver metastases, and is clinically safe and tolerable in combination with FOLFOX chemotherapy.
Mark I. James,Chinenye Iwuji,Glen R.B. Irving,Ankur Karmokar,Jennifer A. Higgins,Nicola Griffin-Teal,Anne L. Thomas,Peter Greaves,Hong Cai,Samita R. Patel,Bruno Morgan,Ashley R. Dennison,Matthew S. Metcalfe,Giuseppe Garcea,David M. Lloyd,David P. Berry,William P. Steward,Lynne M. Howells,Karen Brown +18 more
TL;DR: Curcumin is safe and tolerable in combination with FOLFOX chemotherapy, and is perceived by patients as an acceptable daily adjunct to chemotherapy.
Journal ArticleDOI
Curcumin mediates oxaliplatin-acquired resistance reversion in colorectal cancer cell lines through modulation of CXC-Chemokine/NF-κB signalling pathway
Vicenç Ruiz de Porras,Sara Bystrup,Anna Martínez-Cardús,Raquel Pluvinet,Lauro Sumoy,Lynne M. Howells,Mark I. James,Chinenye Iwuji,Jose Luis Manzano,Laura Layos,Cristina Buges,Albert Abad,Eva Martinez-Balibrea +12 more
TL;DR: It is suggested that combination of OXA + Curcumin could be an effective treatment, for which CXCL1 could be used as a predictive marker, in CRC patients.
Journal ArticleDOI
Functional patient-derived organoid screenings identify MCLA-158 as a therapeutic EGFR × LGR5 bispecific antibody with efficacy in epithelial tumors
Bram Herpers,Berina Eppink,Mark I. James,Carme Cortina,Adrià Cañellas-Socias,Sylvia F. Boj,Xavier Hernando-Momblona,Dominik Glodzik,R C Roovers,Marc van de Wetering,Carina Bartelink-Clements,Vanessa Zondag-van der Zande,Jara García Mateos,Kuan Yan,Lucia Salinaro,Abdul Hafid Basmeleh,Szabolcs Fatrai,David Maussang,Jeroen J. Lammerts van Bueren,Irene Chicote,Garazi Serna,Laia Cabellos,Lorena Ramírez,Paolo Nuciforo,Ramon Salazar,Cristina Santos,Alberto Villanueva,Camille Stephan-Otto Attolini,Elena Sancho,Hector G. Palmer,Josep Tabernero,Michael R. Stratton,John de Kruif,Ton Logtenberg,Hans Clevers,Leo S. Price,Robert G.J. Vries,Eduard Batlle,Mark Throsby +38 more
TL;DR: In this article , a large-scale functional screen of dual-targeting bispecific antibodies (bAbs) on a heterogeneous colorectal cancer PDO biobank and paired healthy colonic mucosa samples was described.
Journal ArticleDOI
Characterization and propagation of tumor initiating cells derived from colorectal liver metastases: trials, tribulations and a cautionary note.
Mark I. James,Lynne M. Howells,Ankur Karmokar,Jennifer A. Higgins,Peter Greaves,Hong Cai,Ashley R. Dennison,Matthew S. Metcalfe,Giuseppe Garcea,David M. Lloyd,David P. Berry,William P. Steward,Karen Brown +12 more
TL;DR: Spheroid outgrowth of metastatic tumor cells across all samples could not be readily achieved using standard spheroid-formation techniques, thus requiring further method validation to reliably propagate cells from the majority of tissues.